New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Alkermes-plc

More Like This

PR Newswire associated0

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

PR Newswire associated0

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

PR Newswire associated0

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)

PR Newswire associated0

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

Gedeon Richter: Cariprazine shows effectiveness in the treatment for dual disorder

ACCESSWIRE associated0

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

Gedeon Richter presents analysis on cannabis usage among patients with schizophrenia: a new medical solution to a severe issue might be available

BD² Expands Foundational Effort to Understand Biology of Bipolar Disorder with $36 Million in New Grants